GRAL
GRAL
NASDAQ · Biotechnology

Grail Inc

$107.97
+27.20 (+33.68%)
As of Sep 21, 9:57 PM ET ·
Day Range $92.00 — $111.50
52W Range $36.98 — $118.84

Performance

1D
1W
1M
3M
6M
1Y +142.74%
YTD +21.49%
Open$93.74
Previous Close$80.77
Day High$111.50
Day Low$92.00
52W High$118.84
52W Low$36.98
Volume
Avg Volume910.3K
Market Cap3.61B
P/E Ratio
EPS$-9.75
SectorBiotechnology

Technical Indicators

Full analysis →
SMA 50 $97.75 Above
SMA 200 $64.49 Above
RSI (14) 50.6 Neutral
Trend Golden Cross Bullish

Analyst Ratings

Buy
15 analysts
9 Buy 6 Hold 0 Sell
Price Target -68.9% upside
Current
$107.97
Target
$33.59
$28.45 $33.59 avg $56.21

Key Financials

FY 2026 FY 2025 FY 2024
Revenue 178.86M 129.26M 2.02B
Net Income -496,264,148 -322,785,093 154.03M
Profit Margin -277.5% -263.6% 7.6%
EBITDA -507,899,701 -348,706,161 214.07M
Free Cash Flow 137.52M
Rev Growth +38.4% +38.4% +15.5%
Debt/Equity 0.96

Biotechnology Peers

Symbol Name Price Change P/E Mkt Cap
ABBV Abbvie Inc $264.48 +0.20% 74.0 466.74B
AMGN Amgen Inc $393.16 +1.95% 23.7 207.25B
GILD Gilead Sciences Inc $150.56 +0.30% 187.10B
VRTX Vertex Pharmaceuticals Inc $510.72 +0.47% 29.7 130.64B
REGN Regeneron Pharmaceuticals $798.17 +1.70% 18.6 80.58B
ALNY Alnylam Pharmaceuticals Inc $244.32 +1.99% 40.0 32.33B